發明
美國
11/064,672
US 7,605,139 B2
DNA癌症疫苗DNA CANCER VACCINES
國防醫學院
2009/10/20
所申請專利為一種可預防和/或減緩和/或抑制膀胱癌細胞生長之醫藥組合物,為一種可有效預防和/或減緩和/或抑制膀胱癌細胞生長之重組DNA癌症疫苗,包含一質體,該質體包含一可編碼產生兩種分枝桿菌抗原的核酸序列,該核酸序列係與一轉錄調控序列相連且與其作用,其中該兩種分枝桿菌抗原係由ESAT6及另一選自85A、85B、Mpt64、PstS3中的牛分枝桿菌抗原所組成。其中該核酸序列更包含一可編碼產生免疫球蛋白κ鏈前導序列之額外的核酸序列,其係與可編碼產生該兩種分枝桿菌抗原之核酸序列相連且與其作用。其中使用載體pCMV-V5-His6來構築該質體,其中該兩種分枝桿菌抗原為重組牛分枝卡介桿菌抗原85A及ESAT6,其中該兩種分枝桿菌抗原為重組牛分枝卡介桿菌抗原85B及ESAT6,其中該兩種分枝桿菌抗原為重組牛分枝卡介桿菌抗原Mpt64及ESAT6,其中該兩種分枝桿菌抗原為重組牛分枝卡介桿菌抗原PstS3及ESAT6。 A recombinant DNA cancer vaccine comprises a plasmid vector comprising a polynucleotide sequence encoding [at least] two mycobacterial antigens operably linked to transcription regulatory elements, the two mycobacterial antigens are recombinant BCG antigens of ESAT6 and another antigen selected from any of 85A, 85B, Mpt64, and PstS3, wherein upon administration to a mammal, said recombinantb DNA cancer vaccine can effectively attenuate or suppress the growth of bladder cancer cells. A composition for treating bladder cancers comprises [at least] four DNA cancer vaccines, wherein each of said DNA cancer vaccines comprises a first plasmid vector comprising a nucleotide sequence encoding [at least] two mycobacterial antigens, which are recombinant BCG antigens of ESAT6 and another antigen selected from any of 85A, 85B, Mpt64, and PstS3; and wherein upon administration to a mammal, said composition can effectively attenuate or suppress the growth of bladder cancer cells.
106-02研發成果審查會同意終止維護專利
研究發展室
(02)8792-3100分機18079
版權所有 © 國家科學及技術委員會 National Science and Technology Council All Rights Reserved.
建議使用IE 11或以上版本瀏覽器,最佳瀏覽解析度為1024x768以上|政府網站資料開放宣告
主辦單位:國家科學及技術委員會 執行單位:台灣經濟研究院 網站維護:台灣經濟研究院